Swedish HTA council warns on umbilical stem cell use
This article was originally published in Clinica
Executive Summary
There have been too few forward-looking, controlled studies which compare results after the transplantation of different types of stem cells, claims the Swedish Council on Technology Assessment in Health Care (SBU). In an alert issued last week, SBU said that the potential advantages and disadvantages attached to using stem cells gained from umbilical cord blood have not yet been properly explained.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.